Article: article from journal or magazin.
Hypertension. L'etude ACCOMPLISH: des résultats vraiment inattendus [The ACCOMPLISH trial: are results really unexpected?]
Revue Médicale Suisse
The ACCOMPLISH trial consists of a randomized morbidity-mortality study involving 11506 hypertensive patients at high cardiovascular risk, randomly allocated to a fixed dose combination containing an angiotensin converting enzyme inhibitor (B, benazepril) and either a calcium antagonist (A, amlodipine) or a diuretic (HCTZ, hydrochlorothiazide). The target blood pressure (< 140/90 mmHg) was achieved after a 6 month titration period in 75.4% of patients receiving B+A, versus 72.4% in those on B + HCTZ. Over a mean follow-up of 3 years, the B + A drug regimen was found to reduce significantly more effectively the relative risk cardiovascular mortality (-20%), fatal and non fatal myocardial infarction (-22%) and coronary revascularization (-14%), appearing therefore particularly effective to prevent complications due to myocardial ischemia.
Amlodipine, Angiotensin-Converting Enzyme Inhibitors, Benzazepines, Calcium Channel Blockers, Diuretics, Humans, Hydrochlorothiazide, Hypertension, Randomized Controlled Trials as Topic
Last modification date